Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 2
Submit an article Journal homepage
122
Views
3
CrossRef citations to date
0
Altmetric
Editorial

The six gaps in the search of neuroprotection for Parkinson’s disease

Alberto J Espay Department of Neurology, University of Cincinnati, 260 Stetson St., Suite 2300, Cincinnati, OH 4526, USA. [email protected]; Department of Neurology, University of Cincinnati, 260 Stetson St., Suite 2300, Cincinnati, OH 4526, USA. [email protected]
,
Alfonso Fasano Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; AFaR-Fatebenefratelli Association for Biomedical Research “San Giovanni Calibita-Fatebenefratelli” Hospital, Isola Tiberina, Rome, Italy; Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; AFaR-Fatebenefratelli Association for Biomedical Research “San Giovanni Calibita-Fatebenefratelli” Hospital, Isola Tiberina, Rome, Italy
&
Francesca Morgante Dipartimento di Neuroscienze, Scienze Psichiatriche ed Anestesiologiche, Università di Messina, Messina, Italy; Dipartimento di Neuroscienze, Scienze Psichiatriche ed Anestesiologiche, Università di Messina, Messina, Italy
Pages 111-113 | Published online: 09 Jan 2014

References

  • Olanow CW, Rascol O, Hauser R et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med.361(13), 1268–1278 (2009).
  • Marras C, McDermott MP, Marek K et al. Predictors of time to requiring dopaminergic treatment in 2 Parkinson’s disease cohorts. Mov. Disord.26(4), 608–613 (2011).
  • Fahn S, Oakes D, Shoulson I et al. Levodopa and the progression of Parkinson’s disease. N. Engl. J. Med.351(24), 2498–2508 (2004).
  • Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson’s disease fundamentally flawed? Mov. Disord.23(6), 784–789 (2008).
  • Tagliati M, Martin C, Alterman R. Lack of motor symptoms progression in Parkinson’s disease patients with long-term bilateral subthalamic deep brain stimulation. Int. J. Neurosci.120(11), 717–723 (2010).
  • Harrison MB, Wylie SA, Frysinger RC et al. UPDRS activity of daily living score as a marker of Parkinson’s disease progression. Mov. Disord.24(2), 224–230 (2009).
  • Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov. Disord.23(6), 837–844 (2008).
  • Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson’s disease: a clinico-pathological study. Brain130(Pt 8), 2123–2128 (2007).
  • Tan EK, Schapira AH. LRRK2 as a therapeutic target in Parkinson’s disease. Eur. J. Neurol.18(4), 545–546 (2011).
  • Di Fonzo A, Rohe CF, Ferreira J et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. Lancet365(9457), 412–415 (2005).
  • Lang AE. A critical appraisal of the premotor symptoms of Parkinson’s disease: potential usefulness in early diagnosis and design of neuroprotective trials. Mov. Disord.26(5), 775–783 (2011).
  • Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology72(15), 1296–1300 (2009).
  • Valappil RA, Black JE, Broderick MJ et al. Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson’s disease. Mov. Disord.25(14), 2296–2303 (2010).
  • Berg D, Seppi K, Behnke S et al. Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch. Neurol.68(7), 932–937 (2011).
  • Abbott RD, Petrovitch H, White LR et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology57(3), 456–462 (2001).
  • Stern MB, Siderowf A. Parkinson’s at risk syndrome: can Parkinson’s disease be predicted? Mov. Disord.25(Suppl. 1), S89–S93 (2010).
  • The Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol.95(4), 629–635 (2011).
  • Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson’s disease. Mov. Disord.26(6), 1049–1055 (2011).
  • Vives-Bauza C, Przedborski S. Mitophagy: the latest problem for Parkinson’s disease. Trends Mol. Med.17(3), 158–165 (2011).
  • Dehay B, Bezard E. New animal models of Parkinson’s disease. Mov. Disord.26(7), 1198–1205 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.